Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with large-cell transformation: A novel histologic finding

Published

Journal Article

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Mycosis fungoides (MF) is the most common variant of cutaneous T-cell lymphomas. Large-cell transformation of MF has been associated with disease progression and overall poor outcome. The expression of CD30, which defines anaplastic large cell lymphoma (ALCL) and lymphomatoid papulosis, might also occur in a subset of patients with MF, with or without large-cell transformation. Brentuximab vedotin is an anti-CD30 monoclonal antibody which has been proven to be a safe and effective therapeutic agent in the treatment of CD30-positive lymphomas, such as Hodgkin lymphoma and ALCL. Recently, brentuximab vedotin has been shown to have a significant clinical activity in treatment-refractory or advanced MF or Sezary syndrome with a wide-range of CD30 expression levels. We report a patient with MF tumor stage with large-cell transformation and low CD30 expression with good response to brentuximab vedotin and unusual extensive xanthomatous changes in the follow-up biopsy.

Full Text

Duke Authors

Cited Authors

  • Buchely, N; Al-Rohil, RN; Aung, PP; Jour, G; Torres-Cabala, C; Prieto, VG; Ivan, D

Published Date

  • September 1, 2018

Published In

Volume / Issue

  • 45 / 9

Start / End Page

  • 711 - 715

Electronic International Standard Serial Number (EISSN)

  • 1600-0560

International Standard Serial Number (ISSN)

  • 0303-6987

Digital Object Identifier (DOI)

  • 10.1111/cup.13288

Citation Source

  • Scopus